Table 2.
Detection of onco-markers preoperatively by MRI.
| Onco-markers | Sequence | Parameter | AUC | Reference |
|---|---|---|---|---|
| IDH mutation | cMRI+DWI+DSC-PWI | mADC+rADC+rCBVmax | 0.92 | (31) |
| MRS | 2-HG | – | (35) | |
| APTw | – | 0.89 | (36) | |
| MGMTpm | Radiomics (TPOT) | 3DT1WI+Gd-3DT1WI+T2WI+FLAIR | 0.951 | (37) |
| iVASO | CBVa | 0.931 | (39) | |
| H3-K27M mutation | DWI | ADC | 0.872 | (41, 42) |
| Ki-67 level | Radiomics (cMRI) | T1WI, T2WI | 0.773 | (43) |
| Radiomics (multicontrast MRI) | ADC+eADC+CBF+PWmap+b1000+ | 0.745 | (47) | |
| b0+T1FLAIR+T2FLAIR+T2FSE+T1C | ||||
| p53 mutation | Radiomics (cMRI) | T2WI | 0.709 | (50) |
| TERT | Radiomics (cMRI+MRS) | CE-T1WI+Flair+T1WI+T2WI | 0.955 | (53) |
| ATRX mutation | Radiomics (cMRI) | T2WI | 0.94 | (56) |
| EGFR amplified | Radiomics (cMRI) | T2WI | 0.95 | (57) |
| DWI | mADC | 0.75 | (58) |
IDH, isocitrate dehydrogenase; rADC, relative apparent diffusion coefficient; 2-HG, 2-hydroxyglutarate; MGMTpm, O6-methylguanine-DNA methyltransferase promoter methylation; TPOT, tree-based pipeline optimization tool; b1,000/b0 DWI with two b-values: b = 0 and b = 1,000 s/mm2; CE-T1WI, contrast-enhanced T1WI; TERT, telomerase reverse transcriptase; ATRX, alpha-thalassemia/mental retardation, X-linked; EGFR, epidermal growth factor receptor; mADC, minimum apparent diffusion coefficient.